ダウン症候群(Down Syndrome):治療薬開発パイプライン動向(世界、2015年上半期版)

【英語タイトル】Down Syndrome - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6186IDB)・商品コード:GMDHC6186IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月30日
・ページ数:55
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界におけるダウン症候群(Down Syndrome)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・ダウン症候群(Down Syndrome)の概要
・ダウン症候群(Down Syndrome)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ダウン症候群(Down Syndrome)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・ダウン症候群(Down Syndrome)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ダウン症候群(Down Syndrome)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Down Syndrome – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Down Syndrome – Pipeline Review, H1 2015’, provides an overview of the Down Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Down Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Down Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Down Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Down Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Down Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Down Syndrome – Overview 8
Pipeline Products for Down Syndrome – Comparative Analysis 9
Down Syndrome – Therapeutics under Development by Companies 10
Down Syndrome – Therapeutics under Investigation by Universities/Institutes 11
Down Syndrome – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Down Syndrome – Products under Development by Companies 15
Down Syndrome – Products under Investigation by Universities/Institutes 16
Down Syndrome – Companies Involved in Therapeutics Development 17
AC Immune SA 17
Eisai Co., Ltd. 18
F. Hoffmann-La Roche Ltd. 19
NeuroNascent, Inc. 20
Transition Therapeutics Inc. 21
Down Syndrome – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ACI-24 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
APH-1104 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVL-8168 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BTD-001 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
donepezil hydrochloride – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ELND-005 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
minocycline – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NNI-351 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RG-1662 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule DYRK1A Inhibitor for CNS Diseases – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Down Syndrome – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit OLIG2 for Down Syndrome – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Down Syndrome – Recent Pipeline Updates 45
Down Syndrome – Discontinued Products 50
Down Syndrome – Product Development Milestones 51
Featured News & Press Releases 51
Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome 51
Apr 07, 2014: Transition Therapeutics Announces Development Update 51
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 53
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 53
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

[List of Tables]
Number of Products under Development for Down Syndrome, H1 2015 8
Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Down Syndrome - Pipeline by AC Immune SA, H1 2015 17
Down Syndrome - Pipeline by Eisai Co., Ltd., H1 2015 18
Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19
Down Syndrome - Pipeline by NeuroNascent, Inc., H1 2015 20
Down Syndrome - Pipeline by Transition Therapeutics Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Down Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 45
Down Syndrome - Discontinued Products, H1 2015 50

[List of Figures]
Number of Products under Development for Down Syndrome, H1 2015 8
Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 24
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

【掲載企業】

AC Immune SA
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
NeuroNascent, Inc.
Transition Therapeutics Inc.

★調査レポート[ダウン症候群(Down Syndrome):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6186IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[ダウン症候群(Down Syndrome):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆